Asco Releases Updated Clinical Practice Guideline On The Use Of Antiemetics For Cancer Patients
The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation.
Alexandria, VA - The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation. The guideline update, which also reviews the likelihood of various cancer treatments to cause vomiting, will be published in the June 20, 2006, print issue of the Journal of Clinical Oncology.
Since the release of an evidence-based clinical practice guideline on the use of antiemetics in 1999, new research is available on treatments to prevent nausea and vomiting in cancer patients. In addition, new cancer treatments such as trastuzumab, which treats advanced breast cancer, and erlotinib, which treats metastatic pancreatic and non-small cell lung cancer, are less likely to cause nausea and vomiting.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
